Drug Trial Radar · NCT00648908
Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial
Last checked: Nov 20, 2026Latest source record: Feb 27, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
269
Actual
Start
Jun 2006
Primary completion
Jan 2011
Study completion Apr 2011
Sponsor
- Lead sponsor
- Acorda TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Apr 1, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability and activity of Fampridine-SR when administered for up to 36 additional months, or until it becomes commercially available whichever comes first, in subjects who previously participated in Acorda Therapeutics Protocol MS-F203.
Conditions
- Multiple Sclerosis
Interventions
Fampridine-SRDrug
Tablets, 10 mg, BID
Primary outcomes
What the sponsor says the trial is designed to measure.
- Summary of Treatment Emergent Adverse Events (TEAE).Time frame: up to 5 years
Locations
32 sites in 2 countries. Site status is shown where the registry gives one.
Barrow Neurology Clinic, St. Joseph's Hospital and Medical Center
Phoenix, Arizona
USC, Keck School of Medicine Health Care Consultation Center
Los Angeles, California
UC Davis
Sacramento, California
Shepherd Center
Atlanta, Georgia
University of Chicago
Chicago, Illinois
Indiana University MS Center
Indianapolis, Indiana
Maryland Center for MS
Baltimore, Maryland
Wayne State University, Department of Neurology
Detroit, Michigan
The Schapiro Center for MS
Golden Valley, Minnesota
Washington University School of Medicine, Div. of Rehab/Neurology
St Louis, Missouri
Advanced Neurology Specialists
Great Falls, Montana
Gimbel MS Center at Holy Name Hospital
Teaneck, New Jersey
Maimonides MS Care Center
Brooklyn, New York
Corinne Goldsmith Dickinson Center for MS
New York, New York
University of Rochester
Rochester, New York
SUNY Stony Brook
Stony Brook, New York
CMC - Neuroscience & Spine Institute, Division of Neurology
Charlotte, North Carolina
Raleigh Neurology Associates
Raleigh, North Carolina
Cleveland Clinic Foundation
Cleveland, Ohio
Ohio State University MS Center
Columbus, Ohio
Oregon Health & Science University, MS Center of Oregon, UHS-42
Portland, Oregon
Thomas Jefferson University Physicians
Philadelphia, Pennsylvania
Allegheny General Hospital, Allegheny Neurological Associates
Pittsburgh, Pennsylvania
University of Texas-Houston
Houston, Texas
Neurological Research Center, Inc.
Bennington, Vermont
Fletcher Allen Health Care
Burlington, Vermont
MS Center at Evergreen
Kirkland, Washington
Foothills Medical Center
Calgary, Alberta, Canada
University of British Columbia, Vancouver Coastal Health Research Institute
Vancouver, British Columbia, Canada
River Valley Health c/o Stan Cassidy Centre for Rehabilitation
Fredericton, New Brunswick, Canada
QEII Health Sciences Centre, Nova Scotia Rehabilitation Centre Site
Halifax, Nova Scotia, Canada
Ottawa Hospital General Campus
Ottawa, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.